Skip to main content
Top
Published in: Diabetologia 10/2009

Open Access 01-10-2009 | Review

Cardiovascular risk assessment scores for people with diabetes: a systematic review

Authors: P. Chamnan, R. K. Simmons, S. J. Sharp, S. J. Griffin, N. J. Wareham

Published in: Diabetologia | Issue 10/2009

Login to get access

Abstract

People with type 2 diabetes have an increased risk of cardiovascular disease (CVD). Multivariate cardiovascular risk scores have been used in many countries to identify individuals who are at high risk of CVD. These risk scores include those originally developed in individuals with diabetes and those developed in a general population. This article reviews the published evidence for the performance of CVD risk scores in diabetic patients by: (1) examining the overall rationale for using risk scores; (2) systematically reviewing the literature on available scores; and (3) exploring methodological issues surrounding the development, validation and comparison of risk scores. The predictive performance of cardiovascular risk scores varies substantially between different populations. There is little evidence to suggest that risk scores developed in individuals with diabetes estimate cardiovascular risk more accurately than those developed in the general population. The inconsistency in the methods used in evaluation studies makes it difficult to compare and summarise the predictive ability of risk scores. Overall, CVD risk scores rank individuals reasonably accurately and are therefore useful in the management of diabetes with regard to targeting therapy to patients at highest risk. However, due to the uncertainty in estimation of true risk, care is needed when using scores to communicate absolute CVD risk to individuals.
Appendix
Available only for authorised users
Literature
1.
go back to reference Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M (1998) Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229–234PubMedCrossRef
2.
go back to reference Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2005) Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28:2901–2907PubMedCrossRef Juutilainen A, Lehto S, Ronnemaa T, Pyorala K, Laakso M (2005) Type 2 diabetes as a “coronary heart disease equivalent”: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 28:2901–2907PubMedCrossRef
3.
go back to reference Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O (2003) Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383–393PubMedCrossRef
4.
go back to reference Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef Gaede P, Lund-Andersen H, Parving HH, Pedersen O (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580–591PubMedCrossRef
5.
go back to reference Stevens RJ, Coleman RL, Holman RR (2005) Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 22:228PubMedCrossRef Stevens RJ, Coleman RL, Holman RR (2005) Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 22:228PubMedCrossRef
6.
go back to reference Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344PubMedCrossRef Yeo WW, Yeo KR (2001) Predicting CHD risk in patients with diabetes mellitus. Diabet Med 18:341–344PubMedCrossRef
7.
go back to reference Eichler K, Puhan MA, Steurer J, Bachmann LM (2007) Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153: 722–731, 731.e1–e8 Eichler K, Puhan MA, Steurer J, Bachmann LM (2007) Prediction of first coronary events with the Framingham score: a systematic review. Am Heart J 153: 722–731, 731.e1–e8
8.
go back to reference Brindle P, Emberson J, Lampe F et al (2003) Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327:1267PubMedCrossRef Brindle P, Emberson J, Lampe F et al (2003) Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ 327:1267PubMedCrossRef
9.
go back to reference Brindle P, Beswick A, Fahey T, Ebrahim S (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92:1752–1759PubMedCrossRef Brindle P, Beswick A, Fahey T, Ebrahim S (2006) Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 92:1752–1759PubMedCrossRef
10.
go back to reference Winocour PH, Fisher M (2003) Prediction of cardiovascular risk in people with diabetes. Diabet Med 20:515–527PubMedCrossRef Winocour PH, Fisher M (2003) Prediction of cardiovascular risk in people with diabetes. Diabet Med 20:515–527PubMedCrossRef
11.
go back to reference Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN (1996) Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) 91:399–413 Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN (1996) Lipid-lowering for prevention of coronary heart disease: what policy now? Clin Sci (Lond) 91:399–413
12.
go back to reference Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003) MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005–2016PubMedCrossRef
13.
go back to reference Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef Colhoun HM, Betteridge DJ, Durrington PN et al (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364:685–696PubMedCrossRef
14.
go back to reference Carroll C, Naylor E, Marsden P, Dornan T (2003) How do people with type 2 diabetes perceive and respond to cardiovascular risk? Diabet Med 20:355–360PubMedCrossRef Carroll C, Naylor E, Marsden P, Dornan T (2003) How do people with type 2 diabetes perceive and respond to cardiovascular risk? Diabet Med 20:355–360PubMedCrossRef
15.
go back to reference Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS (2003) Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26:2777–2784PubMedCrossRef Folsom AR, Chambless LE, Duncan BB, Gilbert AC, Pankow JS (2003) Prediction of coronary heart disease in middle-aged adults with diabetes. Diabetes Care 26:2777–2784PubMedCrossRef
16.
go back to reference Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef Conroy RM, Pyorala K, Fitzgerald AP et al (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 24:987–1003PubMedCrossRef
17.
go back to reference Donnan PT, Donnelly L, New JP, Morris AD (2006) Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 29:1231–1236PubMedCrossRef Donnan PT, Donnelly L, New JP, Morris AD (2006) Derivation and validation of a prediction score for major coronary heart disease events in a U.K. type 2 diabetic population. Diabetes Care 29:1231–1236PubMedCrossRef
18.
go back to reference Yang X, So WY, Kong AP et al (2008) Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101:596–601PubMedCrossRef Yang X, So WY, Kong AP et al (2008) Development and validation of a total coronary heart disease risk score in type 2 diabetes mellitus. Am J Cardiol 101:596–601PubMedCrossRef
19.
go back to reference Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ (2004) Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 11:521–528PubMedCrossRef Stephens JW, Ambler G, Vallance P, Betteridge DJ, Humphries SE, Hurel SJ (2004) Cardiovascular risk and diabetes. Are the methods of risk prediction satisfactory? Eur J Cardiovasc Prev Rehabil 11:521–528PubMedCrossRef
20.
go back to reference McEwan P, Williams JE, Griffiths JD et al (2004) Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21:318–323PubMedCrossRef McEwan P, Williams JE, Griffiths JD et al (2004) Evaluating the performance of the Framingham risk equations in a population with diabetes. Diabet Med 21:318–323PubMedCrossRef
21.
go back to reference Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 22:554–562PubMedCrossRef Guzder RN, Gatling W, Mullee MA, Mehta RL, Byrne CD (2005) Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study. Diabet Med 22:554–562PubMedCrossRef
22.
go back to reference Jimeno Mollet J, Molist Brunet N, Franch Nadal J, Serrano Borraz V, Serrano Barragan L, Gracia Gimenez R (2005) Variability in the calculation of coronary risk in type-2 diabetes mellitus. Aten Primaria 35:30–36 (article in Spanish)PubMedCrossRef Jimeno Mollet J, Molist Brunet N, Franch Nadal J, Serrano Borraz V, Serrano Barragan L, Gracia Gimenez R (2005) Variability in the calculation of coronary risk in type-2 diabetes mellitus. Aten Primaria 35:30–36 (article in Spanish)PubMedCrossRef
23.
go back to reference Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31:2038–2043PubMedCrossRef Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson PM, Gudbjornsdottir S (2008) Risk prediction of cardiovascular disease in type 2 diabetes: a risk equation from the Swedish National Diabetes Register. Diabetes Care 31:2038–2043PubMedCrossRef
24.
go back to reference Coleman RL, Stevens RJ, Retnakaran R, Holman RR (2007) Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30:1292–1293PubMedCrossRef Coleman RL, Stevens RJ, Retnakaran R, Holman RR (2007) Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. Diabetes Care 30:1292–1293PubMedCrossRef
25.
go back to reference Protopsaltis ID, Konstantinopoulos PA, Kamaratos AV, Melidonis AI (2004) Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models. Diabetes Care 27:277–278PubMedCrossRef Protopsaltis ID, Konstantinopoulos PA, Kamaratos AV, Melidonis AI (2004) Comparative study of prognostic value for coronary disease risk between the U.K. prospective diabetes study and Framingham models. Diabetes Care 27:277–278PubMedCrossRef
26.
go back to reference Yang X, So WY, Kong AP et al (2007) Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 30:65–70PubMedCrossRef Yang X, So WY, Kong AP et al (2007) Development and validation of stroke risk equation for Hong Kong Chinese patients with type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 30:65–70PubMedCrossRef
27.
go back to reference Raccah D (2006) Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. Diabetes Metab 32(Spec No 2):2S48–2S51PubMed Raccah D (2006) Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. Diabetes Metab 32(Spec No 2):2S48–2S51PubMed
28.
go back to reference Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172PubMedCrossRef Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27:157–172PubMedCrossRef
29.
30.
go back to reference Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935PubMedCrossRef Cook NR (2007) Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115:928–935PubMedCrossRef
31.
go back to reference Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef Ridker PM, Buring JE, Rifai N, Cook NR (2007) Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297:611–619PubMedCrossRef
32.
go back to reference Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21–29PubMed Cook NR, Buring JE, Ridker PM (2006) The effect of including C-reactive protein in cardiovascular risk prediction models for women. Ann Intern Med 145:21–29PubMed
33.
go back to reference Pepe MS, Feng Z, Gu JW (2008) Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine. Stat Med 27:173–181 doi:10.1002/sim.2929 PubMedCrossRef Pepe MS, Feng Z, Gu JW (2008) Comments on ‘Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond’ by M. J. Pencina et al., Statistics in Medicine. Stat Med 27:173–181 doi:10.​1002/​sim.​2929 PubMedCrossRef
34.
go back to reference Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216PubMedCrossRef Simmons RK, Sharp S, Boekholdt SM et al (2008) Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events? Arch Intern Med 168:1209–1216PubMedCrossRef
35.
go back to reference Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed Day N, Oakes S, Luben R et al (1999) EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 80(Suppl 1):95–103PubMed
36.
go back to reference Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123PubMedCrossRef Pencina MJ, D'Agostino RB (2004) Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 23:2109–2123PubMedCrossRef
37.
go back to reference Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25:3474–3486PubMedCrossRef Chambless LE, Diao G (2006) Estimation of time-dependent area under the ROC curve for long-term risk prediction. Stat Med 25:3474–3486PubMedCrossRef
38.
go back to reference Folsom AR, Chambless LE, Ballantyne CM et al (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166:1368–1373PubMedCrossRef Folsom AR, Chambless LE, Ballantyne CM et al (2006) An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 166:1368–1373PubMedCrossRef
39.
go back to reference Lloyd-Jones DM, Tian L (2006) Predicting cardiovascular risk: so what do we do now? Arch Intern Med 166:1342–1344PubMedCrossRef Lloyd-Jones DM, Tian L (2006) Predicting cardiovascular risk: so what do we do now? Arch Intern Med 166:1342–1344PubMedCrossRef
40.
go back to reference Wald NJ, Hackshaw AK, Frost CD (1999) When can a risk factor be used as a worthwhile screening test? BMJ 319:1562–1565PubMed Wald NJ, Hackshaw AK, Frost CD (1999) When can a risk factor be used as a worthwhile screening test? BMJ 319:1562–1565PubMed
41.
go back to reference Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639PubMedCrossRef Wang TJ, Gona P, Larson MG et al (2006) Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 355:2631–2639PubMedCrossRef
42.
go back to reference Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL (2004) Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109:IV6–IV19PubMed Ridker PM, Brown NJ, Vaughan DE, Harrison DG, Mehta JL (2004) Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109:IV6–IV19PubMed
43.
go back to reference Marteau TM, Weinman J (2006) Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 62:1360–1368PubMedCrossRef Marteau TM, Weinman J (2006) Self-regulation and the behavioural response to DNA risk information: a theoretical analysis and framework for future research. Soc Sci Med 62:1360–1368PubMedCrossRef
44.
go back to reference Hardeman W, Sutton S, Griffin S et al (2005) A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation. Health Educ Res 20:676–687PubMedCrossRef Hardeman W, Sutton S, Griffin S et al (2005) A causal modelling approach to the development of theory-based behaviour change programmes for trial evaluation. Health Educ Res 20:676–687PubMedCrossRef
45.
go back to reference Kinmonth AL, Wareham NJ, Hardeman W et al (2008) Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. Lancet 371:41–48PubMedCrossRef Kinmonth AL, Wareham NJ, Hardeman W et al (2008) Efficacy of a theory-based behavioural intervention to increase physical activity in an at-risk group in primary care (ProActive UK): a randomised trial. Lancet 371:41–48PubMedCrossRef
46.
go back to reference Price HC, Tucker L, Griffin SJ, Holman RR (2008) The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial. Cardiovasc Diabetol 7:21PubMedCrossRef Price HC, Tucker L, Griffin SJ, Holman RR (2008) The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 × 2 factorial understanding risk trial. Cardiovasc Diabetol 7:21PubMedCrossRef
47.
go back to reference Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef Stevens RJ, Kothari V, Adler AI, Stratton IM (2001) The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 101:671–679CrossRef
48.
go back to reference Simmons RK, Coleman RL, Price HC et al (2009) Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 32:708–713PubMedCrossRef Simmons RK, Coleman RL, Price HC et al (2009) Performance of the UK prospective diabetes study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort. Diabetes Care 32:708–713PubMedCrossRef
49.
go back to reference Kothari V, Stevens RJ, Adler AI et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781PubMedCrossRef Kothari V, Stevens RJ, Adler AI et al (2002) UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 33:1776–1781PubMedCrossRef
50.
go back to reference Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298PubMedCrossRef Anderson KM, Odell PM, Wilson PW, Kannel WB (1991) Cardiovascular disease risk profiles. Am Heart J 121:293–298PubMedCrossRef
51.
go back to reference Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP (1979) An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 110:281–290PubMed Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP (1979) An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol 110:281–290PubMed
52.
go back to reference Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97:1837–1847PubMed
53.
go back to reference Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310–315PubMedCrossRef Assmann G, Cullen P, Schulte H (2002) Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation 105:310–315PubMedCrossRef
54.
go back to reference (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 80(Suppl 2):1–29 (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Heart 80(Suppl 2):1–29
55.
go back to reference Hingorani AD, Vallance P (1999) A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 318:101–105PubMed Hingorani AD, Vallance P (1999) A simple computer program for guiding management of cardiovascular risk factors and prescribing. BMJ 318:101–105PubMed
56.
go back to reference WOSCOPS Study Group (1992) A coronary primary prevention study of Scottish men aged 45–64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 45:849–860CrossRef WOSCOPS Study Group (1992) A coronary primary prevention study of Scottish men aged 45–64 years: trial design. The West of Scotland Coronary Prevention Study Group. J Clin Epidemiol 45:849–860CrossRef
57.
go back to reference Marrugat J, Solanas P, D'Agostino R et al (2003) Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 56:253–261 (article in Spanish)PubMedCrossRef Marrugat J, Solanas P, D'Agostino R et al (2003) Coronary risk estimation in Spain using a calibrated Framingham function. Rev Esp Cardiol 56:253–261 (article in Spanish)PubMedCrossRef
58.
go back to reference Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K (2004) Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47:2118–2128PubMedCrossRef Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K (2004) Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 47:2118–2128PubMedCrossRef
59.
go back to reference D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB (1994) Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 25:40–43PubMed D’Agostino RB, Wolf PA, Belanger AJ, Kannel WB (1994) Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study. Stroke 25:40–43PubMed
60.
go back to reference Costa B, Cabre JJ, Martin F, Pinol JL, Basora J, Blade J (2005) The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population. Aten Primaria 35:392–398 (article in Spanish)PubMedCrossRef Costa B, Cabre JJ, Martin F, Pinol JL, Basora J, Blade J (2005) The Framingham function overestimates stroke risk for diabetes and metabolic syndrome among Spanish population. Aten Primaria 35:392–398 (article in Spanish)PubMedCrossRef
Metadata
Title
Cardiovascular risk assessment scores for people with diabetes: a systematic review
Authors
P. Chamnan
R. K. Simmons
S. J. Sharp
S. J. Griffin
N. J. Wareham
Publication date
01-10-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-009-1454-0

Other articles of this Issue 10/2009

Diabetologia 10/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.